Dr. Christina Hoong is a law clerk in the Century City office of Wilson Sonsini Goodrich & Rosati, where she is a member of the firm's patents and innovations group. She focuses on patent prosecution and intellectual property. Christina assists on strategic patent counseling in life sciences and biotechnology, organic and medicinal chemistry, and pharmaceuticals.
Prior to joining the firm, Christina performed her doctoral research on synthesis and design of organometallic compounds and studied the therapeutic effects in cancer. In addition, she has studied using silica nanoparticles for targeted delivery to cancer. Christina’s undergraduate research focused on utilizing transition metals, such as gold, for asymmetric catalysis of small molecules.
Christina is admitted to the U.S. Patent and Trademark Office. She is not yet admitted to any jurisdiction and therefore not yet authorized to practice law.
Dr. Christina Hoong is a law clerk in the Century City office of Wilson Sonsini Goodrich & Rosati, where she is a member of the firm's patents and innovations group. She focuses on patent prosecution and intellectual property. Christina assists on strategic patent counseling in life sciences and biotechnology, organic and medicinal chemistry, and pharmaceuticals.
Prior to joining the firm, Christina performed her doctoral research on synthesis and design of organometallic compounds and studied the therapeutic effects in cancer. In addition, she has studied using silica nanoparticles for targeted delivery to cancer. Christina’s undergraduate research focused on utilizing transition metals, such as gold, for asymmetric catalysis of small molecules.
Christina is admitted to the U.S. Patent and Trademark Office. She is not yet admitted to any jurisdiction and therefore not yet authorized to practice law.
- J.D., University of San Diego School of Law
- Ph.D., Chemistry and Biochemistry, University of California, San Diego
- B.S., Chemical Biology, University of California, Berkeley
- U.S. Patent and Trademark Office
- Not yet admitted to practice in any jurisdiction
- J.D., University of San Diego School of Law
- Ph.D., Chemistry and Biochemistry, University of California, San Diego
- B.S., Chemical Biology, University of California, Berkeley
- U.S. Patent and Trademark Office
- Not yet admitted to practice in any jurisdiction
Select Publications
- Co-author with Y-M. Wang, J. Wu, V. Rauniyar, and F. D. Toste, “Enantioselective Halocyclization Using Reagents Tailored for Chiral Anion Phase-Transfer Catalysis,” 134(31) J. Am. Chem. Soc. 12928-12931, 2012
- Co-author with Y-M. Wang, C. N. Kuzniewski, V. Rauniyar, and F. D. Toste, “Chiral (Acyclic Diaminocarbene)Gold(I)-Catalyzed Dynamic Kinetic Asymmetric Transformation of Propargyl Esters,”133 (33) J. Am. Chem. Soc. 12972-12975, 2011
Select Publications
- Co-author with Y-M. Wang, J. Wu, V. Rauniyar, and F. D. Toste, “Enantioselective Halocyclization Using Reagents Tailored for Chiral Anion Phase-Transfer Catalysis,” 134(31) J. Am. Chem. Soc. 12928-12931, 2012
- Co-author with Y-M. Wang, C. N. Kuzniewski, V. Rauniyar, and F. D. Toste, “Chiral (Acyclic Diaminocarbene)Gold(I)-Catalyzed Dynamic Kinetic Asymmetric Transformation of Propargyl Esters,”133 (33) J. Am. Chem. Soc. 12972-12975, 2011
Seattle-based Seal Rock is a privately held company that focuses on developing treatments for severe diseases with limited or no available therapies. SRT-015 is a second-generation liver-selective inhibitor that will be available in an oral formulation to treat severe acute alcoholic hepatitis as well as orphan liver diseases.
As part of the agreement, Seal Rock is eligible to receive up to €100 million, which includes regulatory, clinical, and commercial milestone payments, plus tiered royalties.
Wilson Sonsini's team advising Seal Rock includes Miranda Biven, Sai Upadhyayula, Ingo Hardt, Jim Malecha, and Christina Hoong.
For more information, please see the press release.
- Privacy Policy
- Terms of Use
- Accessibility